Home › Emphysema › NCT04302272

STRIVE Post-Market Registry Study

The Spiration® Valve System (SVS) Post-Market Registry Study for Severe Emphysema

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Adult patients with shortness of breath and hyperinflation associated with severe emphysema and evidence of low collateral ventilation.
2. Subjects must understand and voluntarily sign an informed consent form.

Exclusion Criteria:

1. Subjects who are not appropriate for SVS therapy based upon the US FDA-approved IFU requirements.
2. Subjects who were withdrawn from this study for any reason will not be allowed to re-enroll.
3. Subjects who have incomplete screening or baseline data.

About the study

This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.

What is being tested

• Spiration Valve System (SVS) (device)

Sponsor: Olympus Corporation of the Americas · Participants: 150 · Started: Oct 9, 2021

Contact the study team

• Courtney Inge · Phone: 703-201-0680
• Sharon Rabine · Phone: 479-644-7840

Official record on ClinicalTrials.gov — NCT04302272

Locations in the U.S.

Conditions

• Emphysema
• COPD

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.